2017 American Transplant Congress
Urine Biomarkers (UBio) Correlate Poorly with Pre-Liver Transplant (LT) Kidney Biopsy Findings and Post-LT Kidney Function.
UBio might be valuable in determining the etiology of renal dysfunction in LT candidates.Aim: Correlate UBio with pre-LT kidney biopsy and post-LT kidney function.Methods:78 LT…2017 American Transplant Congress
An Investigation of Biopsy-Proven De Novo Autoimmune Hepatitis After Hepatitis C Clearance with Direct Acting Antivirals in Liver Transplant Patients.
Department of Abdominal Transplantation, Baylor College of Medicine, Houston, TX
Direct acting antivirals (DAAs) for hepatitis C virus (HCV) have been widely prescribed to post-liver transplant patients for HCV clearance and are believed to be…2017 American Transplant Congress
Multicenter Validation of a Clinicopathologic Risk Score to Predict Hepatocellular Carcinoma Recurrence Following Liver Transplantation: Analysis of 4984 Patients from the US Multicenter HCC Transplant Consortium.
Objective: Recurrence of hepatocellular carcinoma (HCC) following liver transplantation (LT) negatively impacts survival. Existing risk prediction models either lack external validation or limit their scope…2017 American Transplant Congress
Does Cirrhosis Regress in HCV Liver Transplant Recipients Achieving Sustained Virologic Response in the Era of Direct-Acting Antiviral Agents?
Background: Treatment with direct-acting antiviral agents (DAAs) in HCV patients is associated with high sustained virologic response (SVR) rates. It is hoped that cirrhosis regresses…2017 American Transplant Congress
Early Results of the UK REVIVE Trial for Ex-Vivo Liver Warm Blood Perfusion of DCD and DBD Livers Using the Portable Organ Care System (OCS™) Liver Technology.
Hepatobiliary and Transplant Surgery, The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Purpose:TheOCS Liver REVIVE Trial is a single-arm prospective trial to evaluate the safety and performance of OCS™ Liver system to preserve and assess DCD and…2017 American Transplant Congress
Current Status of HIV-to-HIV Transplants in the United States.
1JHU, Baltimore, MD; 2Mount Sinai, New York, NY; 3NIH, Bethesda, MD; 4NYU, New York, NY
The HIV Organ Policy Equity (HOPE) Act allows transplantation using organs from HIV-infected (HIV+) donors for HIV+ individuals in the United States under research protocols.…2017 American Transplant Congress
Prognostic Significance of Preoperative Neutrophil-Lymphocyte Ratio in Patients Undergoing Liver Transplantation with Hepatocellular Carcinoma within Milan Criteria.
Introduction: The systemic inflammation biomarker, neutrophil-to-lymphocyte ratio (NLR) has been reported to be a predioctor of poor survival in patients with various cancers. The purpose…2017 American Transplant Congress
Outcomes Following Transplantation for Hepatocellular Carcinoma.
Transplant, Recanati/Miller Transplantation Institute, New York, Ny
Objectives: To examine the prognostic features and outcomes of patients undergoing transplantation for hepatocellular carcinoma (HCC).Methods: A single-institution retrospective chart review was performed on all…2017 American Transplant Congress
Outcomes of Active Screening for Carbapenem-Resistant Enterobacteriaceae among Liver Transplant Recipients.
Background: Preventive strategies to combat the transmission of Carbapenem-Resistant Enterobacteriaceae (CRE) include the use of active screening for CRE colonization; however, this approach is not…2017 American Transplant Congress
Risk Factors and Outcomes of Intracardiac Thrombosis During Orthotopic Liver Transplantation.
Henry Ford Hospital, Detroit, MI
Introduction: Intracardiac Thrombosis (ICT) during Orthotopic Liver Transplantation (OLT) is an uncommon event associated with high mortality. The incidence of ICT during OLT is estimated…
- « Previous Page
- 1
- …
- 123
- 124
- 125
- 126
- 127
- …
- 180
- Next Page »